Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency
J. Clin. Invest. Neil P. Shah, et al. 117:2562
doi:10.1172/JCI30890 [Go to this article.]

Problems with a PDF?